FORENSIC AND PHARMACEUTICAL ANALYSIS OF ADDICTIVE MORBIDITY BECAUSE OF THE USE OF PSYCHOTROPIC PSYCHOACTIVE SUBSTANCES IN UKRAINE (RETROSPECTIVE ASPECT)

Introduction. The use of psychoactive substances is one of the leading factors in the deterioration of the mental health of the population. The dynamics of addictive morbidity in recent years is closely correlated with each other, as well as with other manifestations of social problems: the general mortality of the population; the number of suicides; the number of crimes committed, which in general affects the development of the country. Materials and methods. The material of the study was statistical data, scientific literature, regulatory documents, and Internet sources. In studying of the problem, used retrospective, documentary, normative and legal, forensic and pharmaceutical methods of analysis. Results and discussion. The article presents the results of the forensic and pharmaceutical analysis of the addictive morbidity in Ukraine for the period of 2005–2008 based on example of psychotropic psychoactive substances. Distinguished three codes of the International Classification of Diseases of the 10th revision, which correspond to the addictive morbidity due to the use of psychotropic substances: F13 – hypnotics and sedatives (diazepam, phenobarbital); F15 – psychostimulants (amphetamine); F16 – hallucinogens (LSD, psilocybin, mescaline). Given the indicators of the listed types of addictive morbidity in Ukraine (per 100 thousand population) in a retrospective aspect. Conclusions. Established, that psychoactive substances from the classification and legal group "psychotropic substances" refer to substances whose circulation is limited at the legislative level. The results of the analysis of the registered addictive morbidity in Ukraine for the period of 2005–2008 because of the use of psychotropic psychoactive substances testify the following. Stability of the index of addictive morbidity because of the use of hypnotic and sedative substances (F13) and hallucinogens (F16) in 2008 in comparison with 2005; about a 24% reduction in the addictive morbidity because of the use of psychostimulants (F15) in 2008 compared with 2005